MA32818B1 - Arylpiperazines et leur emploi en tant qu'antagonistes de alpha2c - Google Patents
Arylpiperazines et leur emploi en tant qu'antagonistes de alpha2cInfo
- Publication number
- MA32818B1 MA32818B1 MA33873A MA33873A MA32818B1 MA 32818 B1 MA32818 B1 MA 32818B1 MA 33873 A MA33873 A MA 33873A MA 33873 A MA33873 A MA 33873A MA 32818 B1 MA32818 B1 MA 32818B1
- Authority
- MA
- Morocco
- Prior art keywords
- antagonists
- arylpiperazine
- alpha
- alpha2c
- activity
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
- C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
- C07D327/06—Six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
LES COMPOSÉS DE FORMULE (I), OÙ X, Z, A, B, D, E, R1-R4 ET M SONT TELS QUE DÉFINIS DANS LES REVENDICATIONS, PRÉSENTENT UNE ACTIVITÉ ANTAGONISTE VIS-À-VIS DE ALPHA2C ET PEUVENT DONC ÊTRE EMPLOYÉS EN TANT QU'ANTAGONISTES DE ALPHA2C.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19335508P | 2008-11-20 | 2008-11-20 | |
PCT/FI2009/000097 WO2010058060A1 (fr) | 2008-11-20 | 2009-11-20 | Arylpipérazines et leur emploi en tant qu'antagonistes de alpha2c |
Publications (1)
Publication Number | Publication Date |
---|---|
MA32818B1 true MA32818B1 (fr) | 2011-11-01 |
Family
ID=41490335
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA33873A MA32818B1 (fr) | 2008-11-20 | 2011-05-20 | Arylpiperazines et leur emploi en tant qu'antagonistes de alpha2c |
Country Status (21)
Country | Link |
---|---|
US (1) | US20110262352A1 (fr) |
EP (1) | EP2364303A1 (fr) |
JP (1) | JP5513515B2 (fr) |
KR (1) | KR20110086747A (fr) |
CN (1) | CN102216282A (fr) |
AR (1) | AR074204A1 (fr) |
AU (1) | AU2009317117A1 (fr) |
BR (1) | BRPI0921669A2 (fr) |
CA (1) | CA2741986A1 (fr) |
CO (1) | CO6382156A2 (fr) |
EA (1) | EA201170711A1 (fr) |
GE (1) | GEP20135959B (fr) |
IL (1) | IL212571A0 (fr) |
MA (1) | MA32818B1 (fr) |
MX (1) | MX2011005367A (fr) |
NZ (1) | NZ592571A (fr) |
TN (1) | TN2011000218A1 (fr) |
TW (1) | TW201024282A (fr) |
UA (1) | UA105647C2 (fr) |
WO (1) | WO2010058060A1 (fr) |
ZA (1) | ZA201103462B (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201139406A (en) * | 2010-01-14 | 2011-11-16 | Glaxo Group Ltd | Voltage-gated sodium channel blockers |
US9624198B2 (en) * | 2013-12-19 | 2017-04-18 | Bayer Pharma Aktiengesellschaft | Substituted piperidinyltetrahydroquinolines |
EP3083594A1 (fr) * | 2013-12-19 | 2016-10-26 | Bayer Pharma Aktiengesellschaft | Utilisation de dérivés de bipipéridinyle substitués comme antagonistes des alpha-2c-adrénorécepteurs |
CA2934134A1 (fr) | 2013-12-19 | 2015-06-25 | Bayer Pharma Aktiengesellschaft | Utilisation de derives de bipiperidinyle substitues comme antagonistes des alpha-2c-adrenorecepteurs |
JOP20200052A1 (ar) | 2013-12-19 | 2017-06-16 | Bayer Pharma AG | بيبريدينيل تتراهيدرو كوينولينات مستبدلة واستخدامها كمعضدات مستقبل أدريني ألفا- 2c |
TWI704145B (zh) | 2015-06-05 | 2020-09-11 | 芬蘭商奧利安公司 | 新醫藥化合物 |
JP2019519582A (ja) * | 2016-06-29 | 2019-07-11 | オリオン コーポレーション | ベンゾジオキサン誘導体およびその医薬用途 |
MA53711A (fr) | 2018-09-25 | 2021-12-29 | Bayer Ag | Antagonistes de récepteur alpha 2-adrénergiques de sous-type c (alpha-2c) pour le traitement de l'apnée du sommeil |
EP3965766A1 (fr) * | 2019-05-09 | 2022-03-16 | Bayer Aktiengesellschaft | Combinaison d'antagonistes d'un sous-type c de récepteur ?2-adrénergique (alpha-2c) avec un bloqueur de canal task1/3 pour le traitement de l'apnée du sommeil |
TW202108135A (zh) | 2019-05-09 | 2021-03-01 | 德商拜耳廠股份有限公司 | 治療睡眠呼吸中止症之α2-腎上腺素受體亞型C (α-2C)拮抗劑與TASK1/3通道阻斷劑之組合 |
CN110615774B (zh) * | 2019-09-19 | 2022-11-11 | 安徽中医药大学 | 具有抗炎活性的苄基哌嗪类化合物、制法及医药用途 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2695295A (en) * | 1952-12-19 | 1954-11-23 | Mcneilab Inc | Unsymmetrical n, n'-substituted ethylenediamine and piperazine compounds |
US3362956A (en) * | 1965-08-19 | 1968-01-09 | Sterling Drug Inc | 1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines |
JPS5515456A (en) | 1978-07-19 | 1980-02-02 | Morishita Seiyaku Kk | 2-substituted-piperazinomethyl-1,4-benzodioxane |
US4788290A (en) * | 1987-12-11 | 1988-11-29 | American Home Products Corporation | Serotonergic pyrazine derivatives |
FI20000480A0 (fi) | 2000-03-01 | 2000-03-01 | Orion Yhtymae Oyj | Kinoliini- ja naftaleenijohdannaisia alfa-2 antagonisteina |
WO2003029239A1 (fr) | 2001-10-04 | 2003-04-10 | Wyeth | Derives de chromane et de benzofurane utilises comme ligands 5-hydroxytryptamine-6 |
EP1490361B1 (fr) | 2002-04-03 | 2007-10-03 | Orion Corporation | Composes polycycliques comme antagonistes puissants des recepteurs alpha2-adrenergiques |
US7091232B2 (en) * | 2002-05-21 | 2006-08-15 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
WO2004067513A1 (fr) | 2003-01-27 | 2004-08-12 | Oy Juvantia Pharma Ltd | Antagonistes pour recepteurs alpha-2 adrenergiques |
TWI457122B (zh) * | 2007-07-20 | 2014-10-21 | Orion Corp | 作為用於治療周邊和中央神經系統疾病之alpha2C拮抗劑的2,3-二氫苯並[1,4]戴奧辛-2-基甲基衍生物 |
-
2009
- 2009-11-19 TW TW098139249A patent/TW201024282A/zh unknown
- 2009-11-20 JP JP2011536911A patent/JP5513515B2/ja not_active Expired - Fee Related
- 2009-11-20 WO PCT/FI2009/000097 patent/WO2010058060A1/fr active Application Filing
- 2009-11-20 US US13/130,102 patent/US20110262352A1/en not_active Abandoned
- 2009-11-20 AR ARP090104487A patent/AR074204A1/es not_active Application Discontinuation
- 2009-11-20 CN CN2009801455410A patent/CN102216282A/zh active Pending
- 2009-11-20 CA CA2741986A patent/CA2741986A1/fr not_active Abandoned
- 2009-11-20 MX MX2011005367A patent/MX2011005367A/es not_active Application Discontinuation
- 2009-11-20 EP EP09763985A patent/EP2364303A1/fr not_active Withdrawn
- 2009-11-20 BR BRPI0921669A patent/BRPI0921669A2/pt not_active IP Right Cessation
- 2009-11-20 AU AU2009317117A patent/AU2009317117A1/en not_active Abandoned
- 2009-11-20 GE GEAP200912264A patent/GEP20135959B/en unknown
- 2009-11-20 NZ NZ592571A patent/NZ592571A/xx not_active IP Right Cessation
- 2009-11-20 UA UAA201107596A patent/UA105647C2/uk unknown
- 2009-11-20 KR KR1020117014010A patent/KR20110086747A/ko not_active Application Discontinuation
- 2009-11-20 EA EA201170711A patent/EA201170711A1/ru unknown
-
2011
- 2011-04-28 IL IL212571A patent/IL212571A0/en unknown
- 2011-05-05 TN TN2011000218A patent/TN2011000218A1/fr unknown
- 2011-05-11 ZA ZA2011/03462A patent/ZA201103462B/en unknown
- 2011-05-20 MA MA33873A patent/MA32818B1/fr unknown
- 2011-05-23 CO CO11063228A patent/CO6382156A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
TN2011000218A1 (en) | 2012-12-17 |
CA2741986A1 (fr) | 2010-05-27 |
EP2364303A1 (fr) | 2011-09-14 |
BRPI0921669A2 (pt) | 2018-06-26 |
CO6382156A2 (es) | 2012-02-15 |
AU2009317117A1 (en) | 2010-05-27 |
WO2010058060A1 (fr) | 2010-05-27 |
GEP20135959B (en) | 2013-11-11 |
AR074204A1 (es) | 2010-12-29 |
NZ592571A (en) | 2013-03-28 |
UA105647C2 (uk) | 2014-06-10 |
IL212571A0 (en) | 2011-06-30 |
JP2012509302A (ja) | 2012-04-19 |
MX2011005367A (es) | 2011-06-20 |
US20110262352A1 (en) | 2011-10-27 |
CN102216282A (zh) | 2011-10-12 |
TW201024282A (en) | 2010-07-01 |
EA201170711A1 (ru) | 2012-01-30 |
JP5513515B2 (ja) | 2014-06-04 |
KR20110086747A (ko) | 2011-07-29 |
ZA201103462B (en) | 2012-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA32818B1 (fr) | Arylpiperazines et leur emploi en tant qu'antagonistes de alpha2c | |
MX2010006143A (es) | Azolilmetiloxiranos, su uso y agentes que lo contienen. | |
UA107672C2 (en) | N-(1,2,5-oxadiazol-3-yl)benzamides and the use thereof as herbicides | |
RS53124B (en) | USE OF BETANECOL FOR THE TREATMENT OF XEROSOMOMY | |
MX2013004491A (es) | Boronatos como inhibidores de arginasa. | |
ATE500250T1 (de) | Azetidinverbindungen als orexin-rezeptor- antagonisten | |
WO2009077471A3 (fr) | Azolylméthyloxiranes, leur utilisation et agents les contenant | |
ECSP12007067A (es) | Derivados de quinazolinona útiles como antagonistas vanilloides | |
CR20120158A (es) | Compuestos de diòxido de iminotiadiazina como inhibidores de bace, composiciones y su uso. | |
BR112013007229A2 (pt) | ''composição,mistura e processo''. | |
MY153915A (en) | Organic compounds | |
MX2010001575A (es) | Derivados de 1,2-diamido-etileno como antagonistas de orexina. | |
PH12012501905A1 (en) | Quinoline derivatives and their use as fungicides | |
BRPI0518752A2 (pt) | 1-alquinil-2-arilàxi-alquil-amidas e uso do mesmo como fungicidas | |
GEP20156230B (en) | Forms of rifaximin and usage thereof | |
FR2964565B1 (fr) | Composition cosmetique comprenant un polymere fixant et un agent antipelliculaire | |
DE602008000754D1 (de) | Tropanverbindungen | |
UA102858C2 (ru) | Производные пиридино-пиридинонов, способ их получения и применения в терапии | |
TW200833324A (en) | Sulfonamide derivatives | |
EA201170132A1 (ru) | 5-гетероциклилалкил-3-гидрокси-2-фенилциклопент-2-еноны в качестве гербицидов | |
MX2009010218A (es) | Derivados de aza-piridopirimidinona. | |
MX2010002341A (es) | Derivados de bencimidazol usados como agonistas del receptor x de farnesoide. | |
RS53586B1 (en) | DERIVATION OF DECISION | |
DE602006009789D1 (de) | Acetylenderivate | |
DE602007004999D1 (de) | 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen-derivate als orexinrezeptor-antagonisten |